NASDAQ:RPRX Royalty Pharma Q2 2026 Earnings Report $56.45 +0.02 (+0.04%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$56.73 +0.28 (+0.50%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Royalty Pharma EPS ResultsActual EPSN/AConsensus EPS $1.27Beat/MissN/AOne Year Ago EPSN/ARoyalty Pharma Revenue ResultsActual RevenueN/AExpected Revenue$789.52 millionBeat/MissN/AYoY Revenue GrowthN/ARoyalty Pharma Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Royalty Pharma Earnings HeadlinesRoyalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Buy" from BrokeragesJuly 10, 2026 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) EVP Sells $508,452.12 in StockJuly 5, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.July 14 at 1:00 AM | Profits Run (Ad)Royalty Pharma, plc (RPRX) Rallied on Earnings BeatJune 29, 2026 | insidermonkey.comRoyalty Pharma, plc (RPRX) Rallied on Earnings BeatJune 29, 2026 | finance.yahoo.comBranded pharmaceuticals stocks Q1 recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)June 15, 2026 | msn.comSee More Royalty Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email. Email Address About Royalty PharmaRoyalty Pharma (NASDAQ:RPRX) is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines. The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors. Royalty Pharma’s portfolio spans multiple therapeutic areas and stages of product life cycles; revenues are derived from sales of underlying drugs in markets around the world. Its business model is positioned to provide liquidity to biopharma owners while assuming the commercial and regulatory risk associated with future product sales. Founded by Pablo Legorreta and headquartered in New York, Royalty Pharma completed a public listing on the Nasdaq under the ticker RPRX in 2020. The company operates globally, collecting royalties generated by product sales in multiple geographies and partnering with a wide range of industry participants. Pablo Legorreta, the company’s founder and long-time leader, has been a central figure in Royalty Pharma’s strategy of building a large, diversified portfolio of biopharma royalty assets.View Royalty Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
